Axsome released 4th quarter financial results today, a couple of highlights from the quarterly and year end release.
- ADHD phase 3 results, first quarter of 2025
- AXS-05 for Alz Agitation NDA to be submitted 2nd half 2025
- AXS-12 for Narcolepsy NDA to be submitted 2nd half 2025
- $315 million in cash, end of 2024
Good quarter, and great 2024 completed. The stock is at an all-time high level around $130.00 per share chart below. Thank you for reading.
